Manfred Hensel

<i>TP53</i> Mutation and Survival in Chronic Lymphocytic Leukemia

Thorsten Zenz, Barbara Eichhorst, Raymonde Busch et al. · Journal of Clinical Oncology · 2010 · 597 citations · Full text

Medicine, Molecular Medicine, Oncology +15

Subcutaneous Alemtuzumab in Fludarabine-Refractory Chronic Lymphocytic Leukemia: Clinical Results and Prognostic Marker Analyses From the CLL2H Study of the German Chronic Lymphocytic Leukemia Study Group

Stephan Stilgenbauer, Thorsten Zenz, Dirk Winkler et al. · Journal of Clinical Oncology · 2009 · 270 citations · Full text

Medicine, Oncology, Pharmacology +17

Prognostic value of end-of-induction PET response after first-line immunochemotherapy for follicular lymphoma (GALLIUM): secondary analysis of a randomised, phase 3 trial

Judith Trotman, Sally F. Barrington, David Belada et al. · The Lancet Oncology · 2018 · 159 citations · Full text

Medicine, Immunology, Oncology +13

Immunochemotherapy with Fludarabine (F), Cyclophosphamide (C), and Rituximab (R) (FCR) Versus Fludarabine and Cyclophosphamide (FC) Improves Response Rates and Progression-Free Survival (PFS) of Previously Untreated Patients (pts) with Advanced Chronic Lymphocytic Leukemia (CLL)

Michael Hallek, Guenter Fingerle-Rowson, Anna Maria Fink et al. · Blood · 2008 · 134 citations

Medicine, Oncology, Pharmacotherapy +14

First-Line Treatment with Fludarabine (F), Cyclophosphamide (C), and Rituximab (R) (FCR) Improves Overall Survival (OS) in Previously Untreated Patients (pts) with Advanced Chronic Lymphocytic Leukemia (CLL): Results of a Randomized Phase III Trial On Behalf of An International Group of Investigators and the German CLL Study Group.

Michael Hallek, Guenter Fingerle-Rowson, Anna‐Maria Fink et al. · Blood · 2009 · 90 citations

Medicine, Oncology, Pharmacotherapy +12